Chau et al. previously identified a population of CD117+ (c-kit) ovarian cancer cells and demonstrated reduced resistance to cisplatin and paclitaxel in a murine model with c-kit knockdown and treatment with imatinib, a tyrosine kinase inhibitor known to target c-kit [30]. This evidence concerns the gene KIT and ovarian carcinoma.